November 4, 2026

Sutro Biopharma to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in several upcoming investor conferences.

Details of the Company's participation are as follows:

Stifel Healthcare Conference
Fireside Chat Date/Time: November 11 at 8:00 AM EST
Location: New York, NY

Truist Securities Biopharma Symposium
Date: November 12
Location: New York, NY

UBS Global Biopharma Conference
Fireside Chat Date/Time: November 17 at 10:40 AM GMT
Location: London, UK

Jefferies Global Healthcare Conference
Fireside Chat Date/Time: November 18 at 1:30 PM GMT
Location: London, UK

Piper Sandler 38th Annual Healthcare Conference
Fireside Chat Date/Time: December 2 at 1:30 PM EST
Location: New York, NY

Where available, live webcasts of the presentations can be accessed on the Events & Presentations page in the Investor Relations section of the Company's website at www.sutrobio.com. Archived replays will remain available for at least 30 days following each event.

About Sutro Biopharma
Sutro Biopharma, Inc. is a clinical-stage biotechnology company advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro's cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what's possible in cancer therapy. The Company's pipeline of single- and dual-payload ADCs targets large oncology markets with

limited treatment options and significant need for improved therapies.

For more information, follow Sutro on social media @Sutrobio or visitwww.sutrobio.com.

Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com

Media Contact
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com

Source: Sutro Biopharma, Inc.